Healthcare Industry News: Perrigo
News Release - October 10, 2006
Hi-Tech Pharmacal Announces the Hiring of Eyal Mares as Vice President, Operations
AMITYVILLE, N.Y.--(HSMN NewsFeed)--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK ), a specialty pharmaceuticals company, announced today that Eyal Mares has joined the Company as Vice President, Operations.Mr. Mares joins Hi-Tech Pharmacal from Perrigo Pharmaceuticals, where he served most recently as Vice President of Operations for Perrigo's New York facility. During his 12 year career with Perrigo Pharmaceuticals and the predecessor company, Clay Park Labs, Mr. Mares also served in a variety of other functions. David Seltzer, President and CEO commented: "We welcome Eyal Mares to our management team and believe that his experience will help Hi-Tech Pharmacal grow and achieve continued success."
Mr. Mares earned a Bachelor of Science in Mechanical Engineering from Ben-Gurion University of the Negev in Israel.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription and OTC products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.
Forward-looking statements (statements which are not historical facts) in this Press Release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Hi-Tech Pharmacal
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
